1. Medtech Insight
  2. >>Device Area

NASS 2020: Medtronic Announces First Patient Implant With InterStim Micro, Adaptix Interbody System Launch

 
• By Marion Webb

Medtronic’s next-generation InterStim Micro system for overactive bladder is more competitive with Axionics’ r-SNM system, according to an analyst. Medtronic continues to innovate as its former CEO announces retirement.

3D illustration of Spine - Part of Human Skeleton.

Medtronic plc kicked off this year’s virtual North American Spine Society (NASS) conference with clinical trial news on its next-generation InterStim Micro sacral neuromodulation (SNM) device for overactive bladder, the launch of the first 3-D printed titanium implant, and announced the final exit of former long-time CEO Omar Ishrak.

Medtronic announced on 6 October, the first day of the four-day NASS meeting, that the first patient has been treated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

More from Device Area

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 
• By Natasha Barrow

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By Marion Webb

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.